Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.
about
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.The Rho GTPase signalling pathway in urothelial carcinoma.Knockdown of fibrous sheath interacting protein 1 expression reduces bladder urothelial carcinoma cell proliferation and induces apoptosis via inhibition of the PI3K/AKT pathway.
P2860
Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.
@ast
Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.
@en
type
label
Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.
@ast
Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.
@en
prefLabel
Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.
@ast
Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.
@en
P2093
P2860
P1476
Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.
@en
P2093
Dan Theodorescu
Kenneth M Felsenstein
Robert T Jones
P2860
P356
10.1016/J.UCL.2015.08.007
P577
2015-10-31T00:00:00Z